Pro/Con: Randomization in phase II clinical trials

In summary, this is a moment in history when we have a large number new agents to investigate in the clinic. The consequence is that we have to use the techniques that are most efficient in terms of identifying effective new therapies and, most importantly, provide each patient with the best opportunity to receive efective therapy. These goals are best served by adequate, efficient phase I studies, well-designed phase II studies, and phase III studies that identify treatments that provide the greatest benefits for our patients.